Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) (clinicaltrials.gov) - Oct 16, 2026 - P3 | N=27 | Terminated | Sponsor: Spanish Breast Cancer Research Group | Trial completion date: Jun 2026 ➔ Dec 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jun 2026 ➔ Dec 2025; Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study completion.
Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR • PIK3CA
|